STOCK TITAN

Avinger to Announce First Quarter 2024 Results on May 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) will announce its first quarter 2024 financial results on May 15, 2024. The commercial-stage medical device company specializes in intravascular image-guided, catheter-based systems for diagnosing and treating vascular diseases. The earnings release will be followed by a conference call and webcast.

Positive
  • None.
Negative
  • None.

REDWOOD CITY, CA / ACCESSWIRE / May 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the first quarter 2024 after the close of trading on Wednesday, May 15, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

To join the call by telephone, please dial +1-973-528-0011 and use passcode 971186. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.

A replay of the webcast will be made available on Avinger's website, www.avinger.com, shortly after completion of the call.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first image-guided, catheter-based system for the diagnosis and treatment of patients with vascular disease in the peripheral and coronary arteries. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices for the treatment of peripheral artery disease (PAD), estimated to affect more than 200 million people worldwide. Avinger is developing its first product application for the treatment of coronary artery disease (CAD), an image-guided system for CTO-crossing in the coronary arteries, which provides the opportunity to redefine a large and underserved market. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Follow Avinger on Twitter and Facebook.

Investor Contact:

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.



View the original press release on accesswire.com

FAQ

When will Avinger announce its first quarter 2024 results?

Avinger will announce its first quarter 2024 financial results on May 15, 2024.

What is Avinger's stock symbol?

Avinger's stock symbol is AVGR.

What does Avinger specialize in?

Avinger is a commercial-stage medical device company specializing in intravascular image-guided, catheter-based systems for diagnosing and treating vascular diseases.

How can I join the conference call?

To join the conference call, dial +1-973-528-0011 and use passcode 971186.

Where can I access the webcast of the conference call?

The webcast will be available online from the investor relations page of Avinger's corporate website at www.avinger.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be made available on Avinger's website, www.avinger.com, shortly after the call.

Avinger, Inc.

NASDAQ:AVGR

AVGR Rankings

AVGR Latest News

AVGR Stock Data

4.68M
1.31M
15.85%
5.88%
3.17%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About AVGR

avinger, inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (pad). pad is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. the company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. avinger’s current lumivascular products include the lightbox imaging console, the ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or ctos, and pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in pad patients.